Drug intelligence / Profile preview

CYC-126

Development stage: Unknown
Lead developer: Cyclerion Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

**CYC-126** is Cyclerion's investigational, individualized **drug-device combination** for **treatment-resistant depression**. The program uses intravenous propofol and dexmedetomidine with a personalized delivery system incorporating real-time electroencephalogram feedback, algorithm-guided dosing, and clinician-operated infusion technology. Cyclerion is developing the approach to guide patients toward anesthetic-induced brain states that may recalibrate dysregulated brain-network activity associated with antidepressant effects. A Phase 2 proof-of-concept study was planned for initiation in the second half of 2026. ([cyclerion.com](https://www.cyclerion.com/))

Targets

GABAA (Gamma-aminobutyric acid receptor)ADRA2A (α2A)

Beyond the preview

Go deeper on CYC-126.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYC-126.

Explore the full profile